Browsing tag:

EGFR


Patients with non-small cell lung cancer, also known as NSCLC, are anxiously awaiting a decision from the FDA’s Oncologic Drugs Advisory Committee regarding Eli Lilly’s introduction of Necitumumab to the already formidable Gemcitabine and Cisplatin combination. Both Gemcitabine and Cisplatin are currently the first line-treatment for patients diagnosed with NSCLC, and the addition of Necitumumab[…]

Read More

Impressive news was revealed from Roche and Exelixis on June 14, 2014 with successful Phase III study results from their melanoma trial. This comprehensive trial involved Exelixis’s Cobimetinib and Zelboraf, which is marketed by Roche, for treating patients with advanced cases of melanoma. All of the 495 patients had specific mutations of the BRAF gene[…]

Read More

Startling news emerged on May 19, 2014 with an ominous report issued from the Pancreatic Cancer Action Network. The report has predicted that pancreatic cancer will become the #2 cause of cancer deaths in the year 2030, bumping colorectal cancer to the third slot. This sobering information comes in response to recent changes in American[…]

Read More

The end of March 2014 brought exciting news from the EU with the announcement of their approval of Cabozantinib for unresectable medullary thyroid carcinoma. Known as the brand name Cometriq and marketed by Exelixis, Cabozantinib works by inhibiting the activity of MET, RET and VEGFR tyrosine kinases. Cases of medullary thyroid carcinoma are virulent and[…]

Read More

The Regorafenib tablet gains EU approval for the treatment of metastasized colorectal cancer (mCRC) in adults, whose disease has progressed even after treatment with standard drugs. Regorafenib was previously approved by the FDA in late May 2012 to treat patients with metastatic colorectal cancer. That initial approval of Regorafenib for unresectable colon cancer was based on the[…]

Read More

What Are Monoclonal Antibodies? A monoclonal antibody is a laboratory-produced molecule that’s carefully engineered to attach to specific defects in your cancer cells. Monoclonal antibodies mimic the antibodies your body naturally produces as part of your immune system’s response to germs, vaccines and other invaders.   Growing Interest for Monoclonal Antibody Therapies Monoclonal antibodies were initially[…]

Read More